Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | SMO | Q99835 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3113463 | 0.90 | KCNA5 (0.48) | KCNA5KCNH2SMOCNR2HTT | |
| SCHEMBL1385352 | 0.87 | KCNA5 (0.53) | KCNA5KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1382239 | 0.87 | KCNA5 (0.53) | KCNA5KCNH2HTTSMN1; SMN2KDM4E | |
| SCHEMBL1383656 | 0.84 | KDM4E (0.53) | KCNA5KCNH2HTTSMN1; SMN2KDM4E | |
| SCHEMBL3124134 | 0.84 | KCNA5 (0.54) | KCNA5KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3115867 | 0.83 | KCNA5 (0.48) | KCNA5KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1385829 | 0.82 | KCNA5 (0.53) | KCNA5KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1381875 | 0.82 | KCNA5 (0.53) | KCNA5KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1384650 | 0.82 | KCNA5 (0.53) | KCNA5KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1381879 | 0.82 | KCNA5 (0.53) | KCNA5KCNH2SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1667979-A4 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
| EP-1667979-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030130-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | KCNQ1, KCNQ2, KCNJ2 | KCNA5 15/4885KCNH2 5/4885SMO 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.